Skip Navigation
Skip to contents

JPTM : Journal of Pathology and Translational Medicine


Author index

Page Path
HOME > Articles and issues > Author index
Ji Won Lee 1 Article
Cyclooxygenase-2 Expression and Its Prognostic Significance in Clear Cell Renal Cell Carcinoma
Ji Won Lee, Jeong Hwan Park, Ja Hee Suh, Kyung Han Nam, Ji-Young Choe, Hae Yoen Jung, Ji Yoen Chae, Kyung Chul Moon
Korean J Pathol. 2012;46(3):237-245.   Published online June 22, 2012
  • 6,826 View
  • 33 Download
  • 14 Citations
AbstractAbstract PDF

The prognostic value of cyclooxygenase-2 (COX-2) in human renal cell carcinoma (RCC) remains unclear. The purposes of this study are to elucidate the clinical significance of COX-2 in clear cell RCC (CCRCC) and to assess the treatment effect of COX-2 inhibition on CCRCC cell lines.


Using tumor samples obtained from 137 patients who had undergone nephrectomy at Seoul National University Hospital, we evaluated COX-2 expression on immunohistochemistry. Moreover, we performed the cell proliferation assay using 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl-2H tetrazolium bromide (MTT) and cell invasion assay. Thus, we evaluated the effect of meloxicam, an inhibitor of COX-2, in two human CCRCC cell lines.


Cancer-specific survival (p=0.038) and progression-free survival (p=0.031) were shorter in the COX-2 high expression group. A multivariate logistic regression model showed that COX-2 expression was an independent risk factor for pTNM stage and Fuhrman nuclear grade. The MTT assay revealed that COX-2 inhibition led to the suppression of the proliferation of CCRCC cell lines. Moreover, it also reduced their invasion capacity.


This study postulates that COX-2 is a poor prognostic indicator in human CCRCC, suggesting that COX-2 inhibition can be a potential therapy in CCRCC.


Citations to this article as recorded by  
  • Flavonoids derived from Anemarrhenae Rhizoma ameliorate inflammation of benign prostatic hyperplasia via modulating COX/LOX pathways
    Xiaotong Cao, Ying Shang, Weigui Kong, Shuqing Jiang, Jun Liao, Ronghua Dai
    Journal of Ethnopharmacology.2022; 284: 114740.     CrossRef
  • The tumor microenvironment and immune targeting therapy in pediatric renal tumors
    Amy B. Hont, Benoit Dumont, Kathryn S. Sutton, John Anderson, Alex Kentsis, Jarno Drost, Andrew L. Hong, Arnauld Verschuur
    Pediatric Blood & Cancer.2022;[Epub]     CrossRef
  • Kirenol, darutoside and hesperidin contribute to the anti-inflammatory and analgesic activities of Siegesbeckia pubescens makino by inhibiting COX-2 expression and inflammatory cell infiltration
    Yu-Sang Li, Jian Zhang, Gui-Hua Tian, Hong-Cai Shang, He-Bin Tang
    Journal of Ethnopharmacology.2021; 268: 113547.     CrossRef
  • Differential expression of cyclooxygenase-2 and cyclin D1 in salivary gland tumors
    Jefferson da Rocha Tenório, Leorik Pereira da Silva, Marília Gabriela de Aguiar Xavier, Thalita Santana, George João Ferreira do Nascimento, Ana Paula Veras Sobral
    European Archives of Oto-Rhino-Laryngology.2018; 275(9): 2341.     CrossRef
  • Retrospective evaluation of COX-2 expression, histological and clinical factors as prognostic indicators in dogs with renal cell carcinomas undergoing nephrectomy
    S. Carvalho, A. L. Stoll, S. L. Priestnall, A. Suarez-Bonnet, K. Rassnick, S. Lynch, I. Schoepper, G. Romanelli, P. Buracco, M. Atherton, E. M. de Merlo, A. Lara-Garcia
    Veterinary and Comparative Oncology.2017; 15(4): 1280.     CrossRef
  • Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib
    Arancha Cebrián, Teresa Gómez del Pulgar, María José Méndez-Vidal, María Luisa Gonzálvez, Nuria Lainez, Daniel Castellano, Iciar García-Carbonero, Emilio Esteban, Maria Isabel Sáez, Rosa Villatoro, Cristina Suárez, Alfredo Carrato, Javier Munárriz-Ferránd
    Scientific Reports.2017;[Epub]     CrossRef
  • COX-2 expression in ovarian cancer: an updated meta-analysis
    Haiming Sun, Xuelong Zhang, Donglin Sun, Xueyuan Jia, Lidan Xu, Yuandong Qiao, Yan Jin
    Oncotarget.2017; 8(50): 88152.     CrossRef
  • COX-2 Expression in Renal Cell Carcinoma and Correlations with Tumor Grade, Stage and Patient Prognosis
    Hedieh Moradi Tabriz, Marzieh Mirzaalizadeh, Shahram Gooran, Farzaneh Niki, Maryam Jabri
    Asian Pacific Journal of Cancer Prevention.2016; 17(2): 535.     CrossRef
  • Lipidomic Signatures and Associated Transcriptomic Profiles of Clear Cell Renal Cell Carcinoma
    Kosuke Saito, Eri Arai, Keiko Maekawa, Masaki Ishikawa, Hiroyuki Fujimoto, Ryo Taguchi, Kenji Matsumoto, Yae Kanai, Yoshiro Saito
    Scientific Reports.2016;[Epub]     CrossRef
  • Intratumoral expression of cyclooxygenase-2 (COX-2) is a negative prognostic marker for patients with cutaneous melanoma
    Łukasz Kuźbicki, Dariusz Lange, Agata Stanek-Widera, Barbara W. Chwirot
    Melanoma Research.2016; 26(5): 448.     CrossRef
  • New Insights on COX-2 in Chronic Inflammation Driving Breast Cancer Growth and Metastasis
    Honor J. Hugo, C. Saunders, R. G. Ramsay, E. W. Thompson
    Journal of Mammary Gland Biology and Neoplasia.2015; 20(3-4): 109.     CrossRef
  • The role of prostaglandin E2 in renal cell cancer development: future implications for prognosis and therapy
    Katarzyna Kaminska, Cezary Szczylik, Fei Lian, Anna M Czarnecka
    Future Oncology.2014; 10(14): 2177.     CrossRef
  • Genomics and epigenomics of clear cell renal cell carcinoma: Recent developments and potential applications
    Małgorzata Rydzanicz, Tomasz Wrzesiński, Hans A.R. Bluyssen, Joanna Wesoły
    Cancer Letters.2013; 341(2): 111.     CrossRef
  • Quantitative Assessment of the Association of COX-2 (Cyclooxygenase-2) Immunoexpression with Prognosis in Human Osteosarcoma: A Meta-Analysis
    Zhe Wang, Maolin He, Zengming Xiao, Hao Wu, Yang Wu, Dominique Heymann
    PLoS ONE.2013; 8(12): e82907.     CrossRef

JPTM : Journal of Pathology and Translational Medicine